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Abstract
Background: A number of observations support the 
involvement of circadian clock genes in the regulation of 
metabolic processes. One of these circadian genes, Per3, 
exhibits a variable number tandem repeat length poly-
morphism, consisting of two alleles, namely four and five 
repeat alleles, in its exon 18. The objective of this study 
was to examine the existence of Per3 variants in patients 
with type 2 diabetes mellitus (T2DM) as compared to a non 
T2DM control group.
Methods: Intravenous blood samples were collected to 
obtain white blood cells from 302 T2DM patients and 330 
non-diabetic, age- and sex-matched, individuals. Per3 
genotyping was performed on DNA by polymerase chain 
reaction.
Results: Frequency of five repeat allele was higher, and 
that of four repeat allele lower, in T2DM patients as com-
pared to non-diabetic controls (χ2 = 6.977, p = 0.0082)
Conclusions: The results indicate an association of Per3 five 
repeat allele with T2DM occurrence and suggest that indi-
viduals with five repeat allele may be at a greater risk for 
T2DM as compared to those carrying the four repeat allele.
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Introduction
The mammalian circadian system is composed of a central 
pacemaker, located in the suprachiasmatic nucleus (SCN) 
of the hypothalamus, and peripheral clocks present in 
almost every cell in the organism [1]. The SCN master clock 
is synchronized by Zeitgebers (photic and non-photic). 
Non-photic Zeitgebers also affect peripheral oscilla-
tors found in organs such as the pancreas, liver, skeletal 
muscle, heart, adipose tissue, intestine, and retina [2–4].
Circadian clock genes are known to regulate circadian 
periodicity through a transcription-translation feedback 
loop, the circadian clock gene Per3 playing an essential 
role in such a feedback loop. Per3 consists of 21 exons of 
which the exon 18 contains a polymorphic repeat domain, 
with four (Per 34) or five (Per35) copies of a tandem repeat 
region with a length of 54 bp sequence encoding 18 amino 
acids [5]. Several studies have reported associations of 
hPer3 alleles with a number of physiopathological condi-
tions, including preference of timing in sleep/wake cycles 
[6, 7], delayed sleep phase syndrome (DSPS) [5–8], and 
sleep homeostasis [9]. In Per3 mutant mice, circadian 
period and phase underwent changes in liver and other 
peripheral tissues [10]. Per3 has also been reported to reg-
ulate adipocyte fate [11].
In humans, the onset of T2DM is recognized to be 
multifactorial and related to, among other processes, the 
timing and extent of food intake and physical exercise 
[12–14], sleep duration, and circadian desynchronization 
[15–18]. Yet, whether there is any association of the Per3 
alleles with T2DM and obesity in humans remains to be 
explored. The objective of the study was to investigate the 
existence of Per3 length polymorphism in type 2 diabetes 
mellitus (T2DM) patients as compared to a group of sex- 
and age-matched non-diabetic controls.
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Materials and methods
Sampling subjects
Blood samples were collected from 302 T2DM individuals 
(age = 50.7 ± 10.3) and 330 healthy non-T2DM individuals (age = 49.9 ± 9.1) 
who served as controls. Among 302 T2DM individuals, 184 were males 
(age = 52.1 ± 9.8) and 118 were females (age = 48.8 ± 10.8). In controls, 
184 were males (age = 50.4 ± 8.9) and 146 females (age = 49.4 ± 3.0). All 
patients were living in Madurai, Tamil Nadu, India. Type 1 diabetes 
patients were excluded from the study.
Control subjects were initially screened randomly based on 
plasma glucose fasting level below 99 mg/dL and were excluded 
from participation if they had diabetes or any family history of dia-
betes [19]. The individuals were categorized as T2DM based on the 
guidelines prescribed by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA, http://
diabetes.niddk.nih.gov/DM/pubs/diagnosis/index.aspx). All the 
patients with diabetes were under usual medication. All the infor-
mation with regard to the protocol was explained and written con-
sents were obtained from participants. The guidelines for the ethical 
treatment of patients in chronobiological studies [20] were followed 
and the experimental protocol was reviewed and approved by the 
Institutional Ethical Committee of the Madurai Kamaraj University, 
Madurai, India.
Per3 genotyping
Genomic DNA was isolated from the blood samples using the phe-
nol-chloroform method. The polymerase chain reaction (PCR) was 
performed using the specific primers as described in [21]. The PCR 
reaction was carried out in 10 µL tubes containing 1 µL of 1 × PCR reac-
tion buffer, 0.5 µL (0.5 mM) of dNTPs mix, 1.5 µL (0.4 mM) Forward/
Reverse Primer mix, 0.05 µL (0.025 U) Taq polymerase enzyme (Genet 
Bio, Daejeon, Korea), 2 µL (100 ng) of genomic DNA and 4.95 µL of 
Milli-Q water. The PCR amplification conditions included an ini-
tial step of 94°C for 5 min, 40 cycles of amplification (94°C for 30 s, 
60.6°C for 30 s, 72°C for 30 s) and a final extension at 72°C for 5 min. 
The resultant PCR products showed three genotypes based on their 
DNA size, characterized as: (i) Per35/5 homozygous allele (401 bp); 
(ii) Per34/4 homozygous allele (347 bp); and (iii) Per34/5 heterozygous 
allele (347 bp and 401 bp). Subsequently, 5% of long repeat and short 
repeat alleles were sequenced for confirmation.
Statistical analysis
Distribution of four and five repeat allele frequencies in the popula-
tion was determined using the Hardy-Weinberg exact test [22]. Devia-
tion from Hardy-Weinberg equilibrium and the association of allele 
frequencies of four and five repeat alleles with T2DM and control 
were analyzed by Chi-square Testing using the Statistical Program 
for Social Science (SPSS) software (Version 20.0; IBM Corp, Armonk, 
NY, USA); p-values lower than 0.05 were taken as evidence of statisti-
cal significance.
Results
Table 1 summarizes genotype and allelic distribution of 
Per3 variants in both groups of individuals. Genotype 
distribution in the three groups was within the limits of 
Hardy-Weinberg equilibrium. No significant deviation was 
found between the observed and expected allele frequen-
cies for T2DM and control groups (p > 0.05). The observed 
genotype frequencies in control and T2DM groups were 
41.2% and 33.8% for Per3 homozygous four repeat allele 
(4/4), 47% and 47.3% for Per3 heterozygous allele (5/4) and 
11.8% and 18.9% for Per3 homozygous five repeat allele 
(5/5), respectively. An increased prevalence of five repeat 
homozygotes was seen in T2DM patients as compared to 
non-diabetic controls (odds ratio = 1.95, confidence inter-
val 95% = 1.21–3.15, p = 0.006).
The allelic distribution of Per3 variants in both groups 
of individuals is summarized in Table 2. Frequency of five 
repeat allele was higher, and that of four repeat allele 
lower, in T2DM patients as compared to non T2DM indi-
viduals (χ2 = 6.977, p < 0.0082).
Discussion
The foregoing results indicate that the Per3 five repeat 
allele could be related to T2DM occurrence and suggest 
Table 1 Genotypic distribution of the 4-/5- length polymorphism of Per3 in type 2 diabetes mellitus (T2DM) patients and controls.
Group   n  
 
Genotypea
4-/4-   4-/5-   5-/5-
T2DM   302   102   143   57
    (34%)   (47%)   (19%)
Control   330   136   155   39
    (41%)   (47%)   (12%)
Odds ratio (95% 
confidence interval)
    1   1.23 (0.87–1.73) p = 0.24   1.95 (1.21–3.15) p = 0.006
a4-, 4-repeat allele; 5-, 5-repeat allele.
Brought to you by | New York University Bobst Library Technical Services
Authenticated
Download Date | 11/28/14 9:03 PM
Karthikeyan et al.: Per3 length polymorphism and diabetes      147
that individuals with five repeat allele could be at a 
greater risk for T2DM as compared to individuals carry-
ing the four repeat allele. Previously, a single nucleotide 
polymorphism (SNP) identified in CRY2, another circa-
dian clock gene, but not in PER3, correlated with T2DM 
[23]. The distribution of Per3 alleles and genotypes were 
found to be in Hardy-Weinberg equilibrium, suggesting 
that genotypic and allele frequencies are constant in the 
population.
Although knowledge of Per3’s role as a component 
of time-keeping system in humans is limited, a number 
of reports indicate that hPer3 can be involved in the 
functioning of sleep [8, 24, 25] and of certain metabolic 
processes [11, 26]. Per3 alleles seem to influence sleep 
homeostasis and sleep/wake timing in individuals [8, 9] 
and a strong correlation has been found between the 
amount of sleep time and Per3 protein secretion in indi-
viduals [27]. Compared to four repeat individuals, five 
repeat individuals tend to experience a greater sense of 
sleep pressure and, further, tend to demonstrate a poorer 
cognitive performance when they are sleep deprived. 
Interestingly, five repeat Per3 allele has been linked to 
DSPS in a Brazilian population [7] as well as to a delayed 
acrophase of melatonin secretion [27]. Exposure of blue 
light decreased melatonin levels to a greater extent in 
individuals carrying the five repeat Per3 allele than in 
four repeat individuals [28]. In contrast, no correlation 
has been found between Per3 genotypes and preference 
of sleep/wake timing [29, 30].
A recent study attributed a major role of Per3 in the 
time keeping of peripheral oscillators present in the liver 
[10]. Per3 could also have a possible functional role in the 
regulation of adipogenesis as constitutive expression of 
Per3 blocked the process of adipogenesis in mesenchymal 
stem cells, whereas elimination of Per3 promoted it [11]. 
Moreover, Per3 mutant mice exhibited a remarkable dif-
ference in their body mass and body composition [26] and 
had more adipose tissue content than wild type mice [11]. 
Per3 is down regulated when cells are maintained under 
gluco-lipotoxic conditions in vitro [31].
A link between prolonged sleep disturbance and the 
increasing worldwide prevalence of the metabolic syn-
drome has been proposed [15, 17, 32]. For instance, it has 
been reported that clock gene expression is impaired in 
individuals with metabolic syndrome, and, further, that 
impairments in transcript levels of PER3 in human leuko-
cytes occur in diabetic subjects and gestational diabetic 
women [33, 34]. Interestingly, mRNA of PER3 has been 
found to be inversely proportional to the glycated hemo-
globin levels in T2DM patients [31, 34]. Taken together, 
these findings suggest that impaired Per3 may influence 
glucose metabolism.
Presence of three phenotypic variants in Per3 could 
be due to differential phosphorylation of proteins. The 
polymorphic repeat consists of a region of putative phos-
phorylation sites and phosphorylation would give rise to 
phenotype difference in individuals. Third repeat inser-
tion/deletion would influence the phosphorylation level, 
thus modifying the behavior of an individual resulting in 
three different behavioral phenotypes [6].
The present study had several limitations that need 
to be considered in any interpretations of its findings. 
Besides its preliminary nature and the necessity for it to 
be confirmed in larger samples of patients and in differ-
ent ethnic populations, the present study did not inves-
tigate the association between the onset of T2DM, body 
mass index and alcohol dependence among patients and 
the genotypic variants of Per3. Such a study is needed to 
substantiate the existence of a direct link between the 
polymorphic variants and their possible association with 
diabetes. Moreover it remains to be explored whether Per3 
directly influences T2DM or indirectly through altered 
sleep/wake cycles or by any other unknown mechanism 
that remains unidentified. Indeed, besides circadian 
changes, other causative factors for the onset of T2DM 
must be considered, including insulin resistance in liver 
Table 2 Four and Five repeat allele distribution of Per3 in type 2 diabetes mellitus (T2DM) patients and controls.
Group   n  
 
Allele (%)   X2   p-Value
4-   5-
T2DM   302   347 (57%)   257 (43%)    
Control   330   427 (65%)   233 (35%)   6.977   0.0082
Odds ratio (95% 
confidence interval)
    0.74 (0.59–0.92)   1.36 (1.08–1.71)   IC 95%(1.081726–1.703075)  
    p < 0.01   p < 0.01    
4-, 4-repeat allele; 5-, 5-repeat allele.
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and abnormal adipogenesis [35], less physical inactivity 
[14], sleep loss [17, 36], sedentary lifestyle [14, 37], and high 
amount of food intake and/or high calorie food consump-
tion [16]. In any event, the findings reported herein are 
compatible with the hypothesis that Per3 five repeat allele 
is associated with a greater risk of T2DM.
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